Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
With over a decade of experience in gene therapy vector development, Creative Biogene offers advanced AAV capsid engineering services aimed at providing efficient and precise solutions for AAV optimization. By integrating rational design and directed evolution technologies, our platform serves research institutions and pharmaceutical companies seeking high-performance AAV vectors. Combining high-throughput screening, AI-driven prediction, and multi-omics analysis, we are dedicated to developing engineered AAV vectors with enhanced tissue specificity, low immunogenicity, and increased packaging capacity to facilitate the translation of gene therapy from bench to bedside.
Gene therapy has emerged as a transformative approach in modern medicine, offering new paradigms for treating genetic disorders, cancer, and neurodegenerative diseases by correcting or replacing defective genes. Adeno-associated virus (AAV) vectors stand out among the various gene delivery systems due to their safety profile, low immunogenicity, and long-term gene expression. However, native AAV vectors face several limitations, such as limited tropism, restricted packaging capacity, and pre-existing immunity, which hinder broader clinical application. Using rational design and directed evolution, Capsid engineering technologies have been developed to overcome these barriers by modifying the viral capsid to enhance its biological properties.

The AAV capsid adopts a T=1 icosahedral symmetry, composed of 60 VP proteins (VP1, VP2, and VP3). VP3 forms the capsid core, while VP1 and VP2 participate in nuclear entry and genome release via their extended N-terminal regions. Key structural features include:
The capsid's surface consists of β-barrel cores and inter-strand loops (e.g., GH loop), forming variable regions (VRs I–IX) that significantly differ among AAV serotypes and influence receptor binding, tropism, and antigenicity.
Creative Biogene offers an integrated service platform for AAV capsid engineering, covering library design and construction, high-throughput screening, in vivo biodistribution analysis, mechanistic studies, and GMP-grade production. Our goal is to help clients develop safer and more efficient AAV-based gene therapy vectors.

Engineering of AAV Capsid Genes
Library Construction
Rational Design
Directed Evolution
Computational Design and Evolution
Variants Screening
In Vitro Cell Models
In Vivo Rodent Models
Clinically Relevant Models
1. Multi-dimensional Technology Integration
Our AAV capsid engineering platform combines rational design, directed evolution, and high-throughput screening to optimize vector performance. Structural modeling and machine learning guide targeted modifications, while large capsid libraries (>109 variants) undergo in vitro/in vivo selection to enrich efficient candidates. Barcode-seq enables pooled screening and NGS-based identification of top-performing variants.
2. Comprehensive Workflow
We offer AAV capsid engineering across 12 serotypes with targeted peptide insertion to ensure diversity and functionality. High-quality AAVs are produced via a triple plasmid system and purified by ultracentrifugation and affinity chromatography. Validation includes in vitro transduction, immunogenicity (ELISA), in vivo targeting, and long-term expression tracking.
3. Core Parameter Optimization
Capsids are optimized for enhanced tissue tropism, immune evasion through epitope mutation, and expanded packaging capacity (up to 5.2 kb), enabling efficient and specific gene delivery.
Creative Biogene provides a comprehensive AAV directed evolution service, covering the entire process from project design to final AAV production. This service enables the development of optimized AAV capsids with improved transduction efficiency, tissue specificity, and therapeutic potential. The workflow includes:

Our services are designed to ensure smooth, efficient, and reliable results. We support every step of the cell line development process:
1Project Consultation & Strategy Design
We start by understanding your specific needs-target tissue, delivery route, and performance criteria-and design a tailored evolution strategy, including library type and screening method.
2Library Construction
AAV capsid libraries are generated using random mutagenesis, DNA shuffling, or peptide insertion. Library diversity and quality are validated by sequencing.
3Library Packaging & QC
The AAV libraries are packaged and assessed for titer and quality to ensure robust diversity and infectivity.
4In Vitro/In Vivo Screening
Directed evolution is performed through 2–5 rounds of selection in cell lines or animal models, enriching for high-performing variants under defined conditions.
5Variant Recovery & Analysis
Enriched variants are recovered and analyzed by sequencing to identify capsids with superior properties.
6Lead Candidate Validation
Top capsids are individually produced and tested for transduction efficiency and tissue specificity in relevant models.
7Large-Scale AAV Production
Final candidates are produced at scale with high purity and titer, ready for downstream research or preclinical applications.
1. Rare Disease Therapies
2. Oncology and Chronic Disease
3. Vaccine Development
Creative Biogene holds nearly 100 plasmids encoding AAV variants with peptide insertions, as cataloged by Buning et al. These resources are readily available for direct AAV vector packaging and further development.
AAV2 VP3 (I-587) Peptide Insert
AAV2 VP3 (I-588) Peptide Insert
Non-AAV2 VP3 Peptide Insert
| Name | Target Cell Type | Insert |
| AAV-I-587 | β1-integrin positive tumor cells | QAGTFALRGDNPQG |
| AAV-588NGR | CD13-positive tumor cells | NGRAHA |
| AAV-MO7A | Tumor cells | RGDAVGV |
| AAV-MO7T | Tumor cells | RGDTPTS |
| AAV-MecA | Tumor cells | GENQARS |
| AAV-MecB | Tumor cells | RSNAVVP |
| rRGD587 | αv-integrin positive tumor cells | CDCRGDCFC |
| AAV-C4 | Tumor cells | PRGTNGP |
| AAV-D10 | Tumor cells | SRGATTT |
| AAV-SIG | Endothelial cells | SIGYPLP |
| AAV-MTP | Endothelial cells | MTPFPTSNEANL |
| AAV-QPE | Endothelial cells | QPEHSST |
| AAV-VNT | Endothelial cells | VNTANST |
| AAV-CNH | Endothelial cells | CNHRYMQMC |
| AAV-CAP | Endothelial cells | CAPGPSKSG |
| AAV-EYH | Smooth muscle cells | EYHHYNK |
| AAV587MTP | Skeletal muscle cells | ASSLNIA |
| AAV-r3.45 | Neuronal stem cells | TQVGQKT |
| AAV2-LSS | CNS | LPSSLQK |
| AAV2-PFG | CNS | WPFYGTP |
| AAV2-PPS | CNS | DSPAHPS |
| AAV2-TLH | CNS | GWTLHNK |
| AAV2-GMN | CNS | GMNAFRA |
| AAV2-7m8 | Retinal cell types | LGETTRP |
| AAV-Kera1 | Keratinocytes | RGDTATL |
| AAV-Kera2 | Keratinocytes | PRGDLAP |
| AAV-Kera3 | Keratinocytes | RGDQQSL |
| AAV-588Myc | None | EQLSISEEDL |
| AAV2-Z34C | Adaptor | Z34C |
| AAV2.N587_R588insBAP | Adaptor | GLNDIFEAQKIEWHE |
| AAV2Ald13 | Adaptor | LCTPSRAALLTGR |
| DMD4 | Vaccine | QVSHWVSGLAEGSFG |
| DMD6 | Vaccine | LSHTSGRVEGSVSLL |
| Name | Target Cell Type | Insert Sequence |
| A588-RGD4C | αv integrin-positive tumor cells | CDCRGDCFC |
| A588-RGD4CGLS | αv integrin-positive tumor cells | CDCRGDCFC |
| AAV-VTAGRAP | Tumor cells | VTAGRAP |
| AAV-APVTRPA | Tumor cells | APVTRPA |
| AAV-DLSNLTR | Tumor cells | DLSNLTR |
| AAV-NQVGSWS | Tumor cells | NQVGSWS |
| AAV-EARVRPP | Tumor cells | EARVRPP |
| AAV-NSVSLYT | Tumor cells (CML) | NSVSLYT |
| AAV-LS1 | Tumor cells (CML), CD34+ cells | NDVRSAN* |
| AAV-LS2 | Tumor cells (CML), CD34+ cells | NESRVLS |
| AAV-LS3 | Tumor cells (CML), CD34+ cells | NRTWEQQ |
| AAV-LS4 | Tumor cells (CML), CD34+ cells | NSVQSSW |
| AAV-RGDLGLS | Tumor cells | RGDLGLS |
| AAV-RGDMSRE | Tumor cells | RGDMSRE |
| AAV-ESGLSQS | Tumor cells | ESGLSQS |
| AAV-EYRDSSG | Tumor cells | EYRDSSG |
| AAV-DLGSARA | Tumor cells | DLGSARA |
| AAV-NDVRSAN | Tumor cells | NDVRSAN* |
| AAV-GPQGKNS | Tumor cells | GPQGKNS |
| AAV-NSSRDLG | Endothelial cells | NSSRDLG |
| AAV-NDVRAVS | Endothelial cells | NDVRAVS# |
| AAV-NDVRSAN | Endothelial cells | NDVRSAN* |
| AAV-NDVRAVS | Endothelial cells | NDVRAVS# |
| AAV-PRSTSDP | Lung (maybe endothelial cells) | PRSTSDP |
| AAV-DIIRA | Endothelial cells | DIIRA |
| AAV-SYENV | Endothelial cells | SYENVASRRPEG |
| AAV-PENSV | Endothelial cells | PENSVRRYGLEE |
| AAV-LSLAS | Endothelial cells | LSLASNRPTATS |
| AAV-NDVWN | Endothelial cells | NDVWNRDNSSKRGGTTEAS |
| AAV-NRTYS | Endothelial cells | NRTYSSTSNSTSRSEWDNS |
| rAAV2-ESGHGYF | Pulmonary endothelial cells | ESGHGYF |
| AAV-GQHPRPG | Cardiomyoblasts | GQHPRPG+ |
| AAV-PSVSPRP | Cardiomyoblasts | PSVSPRP |
| AAV2-VNSTRLP | Cardiomyoblasts | VNSTRLP |
| AAV-GQHPR | Cardiomyoblasts | GQHPRPG+ |
| AAV-LSPVR | Cardiomyoblasts | LSPVRPG |
| AAV-MSSDP | Cardiomyoblasts | MSSDPRRPPRDG |
| AAV-GARPS | Cardiomyoblasts | GARPSEVTTRPG |
| AAV-GNEVL | Cardiomyoblasts | GNEVLGTKPRAP |
| AAV-KMRPG | Cardiomyoblasts | KMRPGAMGTTGEGTRVTRE |
| AAV588MTP | Skeletal muscle | ASSLNIA |
| Serotype | Position | Name | Target Cell Type | Insert |
| AAV1 | I-590 | BAP-AAV1 | Scavidin-displaying BT4C (rat glioma) | GLNDIFEAQKIEWHE |
| AAV1 | I-590 | BAP-AAV1 | Endothelial cells | GLNDIFEAQKIEWHE + CDCRGDCFC |
| AAV1 | I-590 | AAV1-RGD | Tumor cells, endothelial cells | CDCRGDCFC |
| AAV1 | I-590 | AAV1-RGD/BAP (90/10) (mosaic capsid) | Tumor cells, endothelial cells | CDCRGDCFC and GLNDIFEAQKIEWHE |
| AAV1 | I-590 | Tet1c-AAV1 (mosaic capsid) | Tetanus toxin GT1b receptor positive cells | HLNILSTLWKYR |
| AAV1 | I-590a | AAV1.9-3-SKAGRSP | Fibroblast | SKAGRSP |
| AAV3 | I-586 | BAP-AAV3 | Tumor cells | GLNDIFEAQKIEWHE |
| AAV4 | I-586 | BAP-AAV4 | Tumor cells | GLNDIFEAQKIEWHE |
| AAV5 | I-575 | BAP-AAV4 | Tumor cells | GLNDIFEAQKIEWHE |
| AAV5 | I-575 | AAV5-7m8 | Not successful | LGETTRP80 |
| AAV6 | I-585 | AAV6-RGD | Tumor cells | RGD |
| AAV6 | I-585 + Y705-731F + T492V | AAV6-RGD-Y705-731F+T492V | Tumor cells | RGD |
| AAV6 | I-585 + Y705-731F + T492V + K531E | AAV6-RGD-Y705-731F+T492V+K531E | Tumor cells | RGD |
| AAV8 | I-585c | AAV2/8-BP2 | ON-bipolar cells | PERTAMSLP |
| AAV8 | I-590 | AAV8-PRSTSDP | Not successful | PRSTSDP135 |
| AAV8 | I-590 | AAV8-ESGLSOS | Tumor cells | ESGLSOS135 |
| AAV8 | I-590 | AAV8-VNSTRLP | Not successful | VNSTRLP138 |
| AAV8 | I-590 | AAV8-ASSLNIA | Heart (weakly improved transduction) | ASSLNIA122 |
| AAV8 | I-590d | AAV8-PSVSPRP | Not successful | PSVSPRP138 |
| AAV8 | I-590d | AAV8-GQHPRPG | Heart (weakly improved transduction) | GQHPRPG86 |
| AAV8 | I-590d | AAV8-SEGLKNL | Liver | SEGLKNL |
| AAV8 | I-590 | AAV8-7m8 | Not successful | LGETTRP80 |
| AAV9 | I-589 | AAV-SLRSPPS | Endothelial cells, smooth muscle cells | SLRSPPS |
| AAV9 | I-589 | AAV-RGDLRVS | Endothelial cells, smooth muscle cells | RGDLRVS |
| AAV9 | I-589d | AAV9-NDVRAVS | Endothelial cells | NDVRAVS82 |
| AAV9 | I-589d | AAV9-PRSTSDP | Not successful | PRSTSDP135 |
| AAV9 | I-589d | AAV9-ESGLSOS | Tumor cells (weak targeting) | ESGLSOS135 |
| AAV9 | I-588 | AAV-PHP.B | CNS | TLAVPFK |
| AAV9 | I-588 | AAV-PHP.A | CNS | YTLSQGW |
| AAV9 | I-588 | AAV9-7m8 | Retinal cells | LGETTRP80 |
| AAV9P1 | Not disclosed | AAV9P1 | Neuronal progenitor cells | RGDLGLS |
Ready to advance your AAV vector development with high-performance capsid engineering? Contact Creative Biogene today to explore how our AAV capsid-directed evolution service can accelerate your gene therapy pipeline.
Q: Why are positions I-587 and I-588 on AAV2 frequently used for peptide insertion?
A: Positions I-587 and I-588 are located near the threefold protrusions on the AAV2 capsid surface, which are tolerant to insertions without disrupting capsid assembly or genome packaging. Studies have shown that up to 34-amino-acid-long peptides can be inserted here, enabling redirection of viral tropism and functional enhancement of vector properties.
Q: What are the key structural features of the AAV capsid relevant to engineering?
A: The AAV capsid is a T=1 icosahedral structure assembled from 60 VP subunits (mostly VP3), featuring:
Q: What additional support do you offer beyond vector design?
A: Creative Biogene and its partners offer end-to-end services including:
Q: Can I order a ready-to-use engineered AAV vector?
A: Yes. A wide library of engineered AAV vectors is available as off-the-shelf products. Custom orders are also welcome, and timelines are optimized for fast project turnover, typically within 1-4 weeks depending on complexity.
References: